Darbepoetin alpha in lower-than-equimolar doses maintains haemoglobin levels in stable haemodialysis patients converting from epoetin alpha/beta

Nephrology Dialysis Transplantation

Volumn 23, Issue 1, 2008, Pages 301-308

  Bock, H Andreas ^a,g   Hirt Minkowski, Patricia ^b   Brünisholz, Michel ^c   Keusch, Gerald ^d   Rey, Simone ^e   Von Albertini, Beat ^f  

^a CANTONAL HOSPITAL AARAU   (Switzerland)

^b Regionalspital Emmental   (Switzerland)

^c Hopital Regional   (Switzerland)

^d Surgical Department   (Switzerland)

^e PFC Pharma Focus Ltd   (Switzerland)

^f Clinique Cecil   (Switzerland)

^g Division of Nephrology   (Switzerland)

Author keywords

Anaemia; Darbepoetin; End stage renal disease; Epoetin; Haemoglobin

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT; DRUG DERIVATIVE; ERYTHROPOIETIN;

ADULT; AGED; ALGORITHM; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COST CONTROL; DIZZINESS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FEVER; GASTROINTESTINAL DISEASE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; INFECTION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; SHIVERING; SIDE EFFECT; SWEATING; SWITZERLAND; BLOOD; CHRONIC KIDNEY FAILURE; RENAL REPLACEMENT THERAPY;

AGED; EPOETIN ALFA; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; RENAL DIALYSIS;

EID: 44449099182     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm579     Document Type: Article

References (14)

1. Egrie JC, Grant JR, Gillies DK, Aoki KH, Strickland TW. The role of carbohydrate on the biological activity of erythropoietin. Glycoconjugate J 1993; 10: 263 (abstract)
2. Mac Dougall I, Gray SJ, McEvoy O et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with Epoetin alpha in dialysis patients. J Am Soc Nephrol 1999; 10: 2392-2395
3. Canaud B. darbepoetin alpha dose requirements for IV and SC administration are equivalent in anaemic dialysis patients. Nephrol Dial Transplant 2002; 17 [Suppl 12]: 137, (Abstract M319)
4. Vanrenterghem Y, Barany P, Mann JFE et al. Randomized trial of darbepoetin alpha for treatment of renal anaemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int 2002; 62: 2167-2175
5. Locatelli F. darbepoetin alpha unit dosing is effective for treating renal anaemia. Oral presentation at the 39th congress of the ERA-EDTA 2002 in Copenhagen, July 2002.
6. Locatelli F, Canaud B, Giacardy F, Martin-Malo A, Baker N, Wilson J. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alpha at reduced dose frequency relative to recombinant human erythropoietin (rHuEPO). Nephrol Dial Transplant 2003; 18: 362-369
7. Locatelli F, Walker R, Wilkie M et al. Novel erythropoiesis stimulating protein for treatment of anaemia in chronic renal insufficiency. Kidney Int 2001; 60: 741-747
8. Suranyi MG, Lindberg JS, Navarro J, Elias C, Brenner RM, Walker R. Treatment of anaemia with darbepoetin alpha administered de novo once every other week in chronic kidney disease. Am J Nephrol 2003; 23: 106-11
9. Scott SD. Dose conversion from recombinant human erythropoietin to darbepoetin alpha: recommendations from clinical studies. Pharmacotherapy 2002; 22: 160S-165S
10. Nissenson AR. Dosing darbepoetin alpha. Am J Kidney Dis 2002; 40: 872-873 (letter)
11. Roger SD, Cooper B. What is the practical conversion dose when changing from epoetin alpha to darbepoetin outside of clinical trials? Nephrology 2004; 9: 223-228
12. Deray G. Dosing darbepoetin alpha continued. Am J Kidney Dis 2003; 41: 1334 (letter)
13. Tolman C, Richardson D, Bartlett C, Will E. Structured conversion from thrice weekly to weekly erythropoietic regimens using a computerized decision-support system: a randomized clinical study. J Am Soc Nephrol 2005; 16: 1463-1470
14. Centers for Medicare and Medicaid services: Payment for Epogen, Procrit, and Aranesp under the Medicare Outpatient Prospective Payment System (OPPS), 2003. (http://www.cms.hhs.gov/hospitaloutpatientpps/downloads/cms-1206- fc_factsheet2.zip).